Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

Transfus Apher Sci. 2021 Oct;60(5):103242. doi: 10.1016/j.transci.2021.103242. Epub 2021 Aug 13.

Abstract

Background and objectives: Extracorporeal photopheresis (ECP) is one of the second-line treatment strategies in steroid-refractory acute graft-versus-host disease (aGvHD). We aimed to share our multicenter experience using ECP in our steroid-refractory aGvHD patients.

Materials and methods: A retrospective observational series of 75 aGvHD patients from 4 transplant centers were analyzed. All ECP procedures were performed with the off-line system. All patients received ECP as second-line therapy.

Results: 74.7 % of aGvHD patients were grade 3 or 4. The overall response rate was 42.7 % (32/75) in aGvHD including 17 complete responses (22.7 %). Median follow-up was 6 months (range, 1-68). Median overall survival (OS) was 5 months for non-responders and 68 months for responders (p < 0.001). Twenty-seven (36 %) patients are alive, and 48 (64 %) patients have died.

Conclusions: Early initiated ECP could be an effective treatment alternative in patients with steroid-refractory aGvHD.

Keywords: Acute graft versus host disease; Allogeneic stem cell transplantation; Extracorporeal photopheresis.